Chris Reist

Dr. Chris Reist

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2006 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
VOVural Ozdemir
Vural Ozdemir
BWBryn Williams-Jones
Bryn Williams-Jones
SGStephen J Glatt
Stephen J Glatt
MTMing T Tsuang
Ming T Tsuang
JLJames B Lohr
James B Lohr
CRChris Reist
Chris Reist

30 April 2001 in American Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
CRChris Reist
Chris Reist
CMChiara Mazzanti
Chiara Mazzanti
RVRyan Vu
Ryan Vu
DTDominic Tran
Dominic Tran
DGDavid Goldman
David Goldman

27 July 2022 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
JDJoAnn Difede
JoAnn Difede
BRBarbara Rothbaum
Barbara Rothbaum
Albert RizzoAlbert Rizzo
Albert Rizzo
KWKatarzyna Wyka
Katarzyna Wyka
LSLisa Spielman
Lisa Spielman
FLFrancis S. Lee
Francis S. Lee
Posttraumatic stress disorder (PTSD) is a significant public health issue. Yet, there are limited treatment options and no data to suggest which treatment will work for whom. We tested the efficacy of virtual reality exposure (VRE) or prolonged imaginal exposure (PE), augmented with D-cycloserine (DCS) for combat-related PTSD. As an exploratory aim, we examined whether brain-derived neurotrophic factor (BDNF) and fatty acid amide hydrolase (FAAH) moderated treatment response. Military personnel with PTSD (n = 192) were recruited into a multisite double-blind randomized controlled trial to receive nine weeks of VRE or PE, with DCS or placebo. Primary outcome was the improvement in symptom severity. Randomization was stratified by comorbid depression (MDD) and site. Participants in both VRE and PE showed similar meaningful clinical improvement with no difference between the treatment groups. A significant interaction (p = 0.45) suggested VRE was more effective for depressed participants (CAPS difference M = 3.51 [95% CI 1.17–5.86],p = 0.004, ES = 0.14) while PE was more effective for nondepressed participants (M = −8.87 [95% CI −11.33 to −6.40],p < 0.001, ES = −0.44). The main effect of DCS vs. placebo was not significant. Augmentation by MDD interaction (p = 0.073) suggested that depressed participants improved more on placebo (M = −8.43 [95% CI −10.98 to −5.88],p < 0.001, ES = −0.42); DCS and placebo were equally effective for nondepressed participants. There was an apparent moderating effect of BDNF Val66Met polymorphism on DCS augmentation (ES = 0.67). Met66 allele carriers improved more on DCS (ES = −0.25). FAAH 385 A carriers improved more than non-carriers (ES = 0.33), particularly those with MDD (ES = 0.62). This study provides a step toward precision therapeutics for PTSD by demonstrating that comorbid MDD and genetic markers may help guide treatment selection.ClinicalTrials.gov Identifier: NCT01352637.

1 December 2001 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
CRChris Reist
Chris Reist
JDJohn Gregory Duffy
John Gregory Duffy
KFKen Fujimoto
Ken Fujimoto
LCLarry Cahill
Larry Cahill
Emotional arousal has been shown to enhance memory, an effect that is blocked by propranolol suggesting that the noradrenergic system is important in

1 May 2007 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
CRChris Reist
Chris Reist
VOVural Ozdemir
Vural Ozdemir
EWEric Wang
Eric Wang
MHMehrtash Hashemzadeh
Mehrtash Hashemzadeh
SMSteven Mee
Steven Mee
RMRobert Moyzis
Robert Moyzis

4 May 2020 in CNS Spectrums
Verified
Journal Article
Closed access
PDF file
CRChris Reist
Chris Reist
ESElani Streja
Elani Streja
CTCynthia Crystal Tang
Cynthia Crystal Tang
BSBryan Shapiro
Bryan Shapiro
JMJim Mintz
Jim Mintz
MHMichael Hollifield
Michael Hollifield
Background: Prazosin has been an accepted treatment for patients with post-traumatic stress disorder (PTSD) who experience sleep disturbances, including nightmares. Results of a recent large randomized control trial did not find benefit of prazosin vs placebo in improving such outcomes. A meta-analysis that includes this most recent trial was conducted to examine the pooled effect of prazosin vs placebo on sleep disturbances and overall PTSD symptoms in patients with PTSD.Methods: A systematic review of the published literature on trials comparing prazosin vs placebo for improvement of overall PTSD scores, nightmares, and sleep quality was conducted. Hedges’ g standardized mean differences (SMD) between prazosin and placebo were calculated for each outcome across studies.Results: Six randomized placebo-controlled studies representing 429 patients were included in the analysis, including two studies with a crossover design. Results showed prazosin significantly improved overall PTSD scores (SMD = −0.31; 95% confidence intervals [CI]: −0.62, −0.01), nightmares (SMD = −0.75; 95% CI: −1.24, −0.27), and sleep quality (SMD = −0.57; 95% CI: −1.02, −0.13). In the largest trial, prazosin showed a reduction in clinical outcome measures similar to past studies, but a relatively large placebo effect size, particularly for nightmares, contributed to no treatment differences.Conclusions: Despite the results of a recent, large randomized study, pooled effect estimates show that prazosin has a statistically significant benefit on PTSD symptoms and sleep disturbances. Limitations that should be considered include heterogeneity of study design and study populations as well as the small number of studies conducted and included in this meta-analysis.